{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:06:02Z","timestamp":1784099162252,"version":"3.55.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine in children and adolescents not only impacts academic pursuits and family life but also have secondary psychological effects. Determining the role of acute medication for migraine treatment in this population can reduce the burden associated with migraine. This network meta-analysis aimed to identify the relative efficacy and safety of acute migraine drug in children and adolescents migraine populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Cochrane Register of Controlled Trials and MEDLINE via PubMed and Embase databases were searched from inception to August 2025, only published studies in English. Double-blind randomized clinical trials evaluating the currently available acute treatments for childhood and adolescent migraines were included. The primary efficacy endpoint was pain freedom at 2\u00a0hours. Secondary efficacy endpoints included the proportion of participants with pain relief at 2\u00a0hours, pain freedom from two to 24\u00a0h, and the proportion using rescue drugs after 2\u00a0hours and up to 24\u00a0h. Adverse events (AEs) were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 30 studies (involving 8,914 participants and 13 pharmacological interventions). All treatments included demonstrated higher odds ratios (ORs) compared with the placebo for pain freedom at 2\u00a0hours. Dihydroergotamine was associated with the highest ORs, but its confidence interval included null values. Sumatriptan\/naproxen sodium, ibuprofen, zolmitriptan nasal spray, sumatriptan nasal spray, and rizatriptan showed statistical significance. Sumatriptan\/naproxen sodium yielded the highest odds (OR: 2.91, 95% CI: 1.87\u20134.53), followed by ibuprofen (OR: 2.88, 95% CI: 1.47\u20135.64), and rizatriptan showed the lowest (OR: 1.51, 95% CI: 1.23\u20131.86). Only sumatriptan\/naproxen sodium was associated with a significantly higher OR compared with placebo for pain freedom from two to 24\u00a0h (OR: 2.31, 95% CI: 1.31\u20134.07). Ibuprofen exhibited the highest effect size for pain relief at 2\u00a0hours (OR: 3.21, 95% CI: 1.10\u20139.34). None of the included drugs was found to reduce the use of rescue drugs from two to 24\u00a0h. Zolmitriptan was associated with the highest risk of AEs among all treatments. Acetaminophen appears to have the lowest risk of adverse events, comparable to that of a placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ibuprofen can effectively relieve symptoms, characterized by a favorable benefit-risk profile. Sumatriptan and zolmitriptan nasal sprays also exhibited robust efficacy, specifically among populations with prominent nausea and vomiting. Sumatriptan\/naproxen sodium merits consideration, especially in patients exhibiting an inadequate response to monotherapy. Dihydroergotamine demonstrated potential benefits in refractory and chronic migraine; however, high-quality studies are warranted to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1851994","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:11:24Z","timestamp":1784095884000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug interventions for acute treatment of pediatric migraine: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi","family":"Cheng","sequence":"first","affiliation":[{"name":"College of Traditional Chinese Medicine, Hebei University","place":["Baoding, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Li","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Hebei University","place":["Baoding, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, China-Japan Friendship Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglu","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate School of Beijing University of Chinese Medicine","place":["Beijing, China"]},{"name":"Qingdao Municipal Hospital","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/B978-0-12-823357-3.00034-3","article-title":"Management of migraine in children and adolescents","volume":"199","author":"Abu-Arafeh","year":"2024","journal-title":"Handb. Clin. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1212\/WNL.0b013e318271f812","article-title":"Migraine and migraine subtypes in preadolescent children: association with school performance","volume":"79","author":"Arruda","year":"2012","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/nejmra1915327","article-title":"MIgraine","volume":"383","author":"Ashina","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.297.13.1443","article-title":"Sumatriptan-naproxen for acute treatment of migraine: a randomized trial","volume":"297","author":"Brandes","year":"2007","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5863\/1551-6776-13.1.17","article-title":"The treatment of migraine headaches in children and adolescents","volume":"13","author":"Brenner","year":"2008","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ Clin. Research ed."},{"key":"B7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3810\/pgm.2014.03.2743","article-title":"Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85\/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?","volume":"126","author":"Calhoun","year":"2014","journal-title":"Postgrad. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13312-023-2968-0","article-title":"The efficacy of different triptans for the treatment of acute headache in pediatric migraine: a systematic review","volume":"60","author":"Chanchlani","year":"2023","journal-title":"Indian Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11916-024-01213-x","article-title":"Triptans in the acute migraine management of children and adolescents: an update","volume":"28","author":"Chatterjee","year":"2024","journal-title":"Curr. Pain Headache Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1411","DOI":"10.1542\/peds.2011-2455","article-title":"Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine","volume":"129","author":"Derosier","year":"2012","journal-title":"Pediatrics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1007\/s00415-008-0984-6","article-title":"Migraine-associated risks and comorbidity","volume":"255","author":"Diener","year":"2008","journal-title":"J. Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","article-title":"Guidelines of the international headache society for controlled trials of acute treatment of migraine attacks in adults","volume":"39","author":"Diener","year":"2019","journal-title":"Cephalalgia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/jamapediatrics.2022.3940","article-title":"Anxiety and depressive symptoms and disorders in children and adolescents with migraine: a systematic review and meta-analysis","volume":"176","author":"Falla","year":"2022","journal-title":"JAMA Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","article-title":"Migraine","volume":"8","author":"Ferrari","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/phmt.s334744","article-title":"Management of chronic migraine in children and adolescents: where are we in 2022? Pediatric health","volume":"13","author":"Gibler","year":"2022","journal-title":"Med. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3331024251413283","DOI":"10.1177\/03331024251413283","article-title":"Management of migraine in children and adolescents: a systematic review of guidelines and practice recommendations","volume":"46","author":"Hassan","year":"2026","journal-title":"Cephalalgia An International Journal Headache"},{"key":"B19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1177\/0333102412451358","article-title":"Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design","volume":"32","author":"Ho","year":"2012","journal-title":"Cephalalgia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Internal Medicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/life12040536","article-title":"Emerging pharmacological treatments for migraine in the pediatric population","volume":"12","author":"Iannone","year":"2022","journal-title":"Life (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1177\/0333102417736902","article-title":"Treatment of acute migraine attacks in children with analgesics on the world health organization essential medicines list: a systematic review and GRADE evidence synthesis","volume":"38","author":"Jeric","year":"2018","journal-title":"Cephalalgia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1756285615616586","article-title":"The optimal management of headaches in children and adolescents","volume":"9","author":"Kacperski","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/brainsci15030280","article-title":"Current trends in pediatric migraine: clinical insights and therapeutic strategies","volume":"15","author":"Khan","year":"2025","journal-title":"Brain Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1371\/journal.pmed.0050172","article-title":"Children are not just small adults: the urgent need for high-quality trial evidence in children","volume":"5","author":"Klassen","year":"2008","journal-title":"PLoS Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e2438666","DOI":"10.1001\/jamanetworkopen.2024.38666","article-title":"Preventive medications in pediatric migraine: a network meta-analysis","volume":"7","author":"Kohandel","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"382","DOI":"10.18553\/jmcp.2017.23.3.382","article-title":"Off-Label prescribing for children with migraines in U.S. ambulatory care settings","volume":"23","author":"Lai","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1073\/pnas.0306147101","article-title":"Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B\/1D receptor agonists","volume":"101","author":"Levy","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1526-4610.1994.hed3410578.x","article-title":"Treatment of childhood headache with dihydroergotamine mesylate","volume":"34","author":"Linder","year":"1994","journal-title":"Headache"},{"key":"B31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1468-2982.2008.01806.x","article-title":"Consistency of response to sumatriptan\/naproxen sodium in a placebo-controlled, crossover study","volume":"29","author":"Lipton","year":"2009","journal-title":"Cephalalgia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/0333102413515351","article-title":"Adding NSAIDs to triptans: could less be more?","volume":"34","author":"Loder","year":"2014","journal-title":"Cephalalgia An International Journal Headache"},{"key":"B33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/wco.0000000000000935","article-title":"Targets for migraine treatment: beyond calcitonin gene-related peptide","volume":"34","author":"Moreno-Ajona","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s10194-023-01541-0","article-title":"Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis","volume":"24","author":"Onofri","year":"2023","journal-title":"J. Headache Pain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1212\/WNL.0000000000008095","article-title":"Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the Guideline Development, Dissemination, and Implementation subcommittee of the American Academy of Neurology and the American Headache Society","volume":"93","author":"Oskoui","year":"2019","journal-title":"Neurology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst. Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamapediatrics.2020.1422","article-title":"Short-term treatment of migraine in children and adolescents","volume":"174","author":"Patniyot","year":"2020","journal-title":"JAMA Pediatr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"CD005220","DOI":"10.1002\/14651858.CD005220.pub2","article-title":"Drugs for the acute treatment of migraine in children and adolescents","volume":"4","author":"Richer","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12874-021-01397-5","article-title":"Predictive P-score for treatment ranking in Bayesian network meta-analysis","volume":"21","author":"Rosenberger","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1526-4610.2006.00313.x","article-title":"Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents","volume":"46","author":"Rothner","year":"2006","journal-title":"Headache"},{"key":"B42","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"Rucker","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Stat. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/head.13700","article-title":"Dihydroergotamine (DHE) - then and now: a narrative review","volume":"60","author":"Silberstein","year":"2020","journal-title":"Headache"},{"key":"B46","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/head.14117","article-title":"Dihydroergotamine infusion for pediatric refractory headache: a retrospective chart review","volume":"61","author":"Srouji","year":"2021","journal-title":"Headache"},{"key":"B47","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1526-4610.2004.04171.x","article-title":"Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies","volume":"44","author":"Visser","year":"2004","journal-title":"Headache"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14737175.2024.2401558","article-title":"Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine","volume":"24","author":"Wells-Gatnik","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1542\/peds.106.5.989","article-title":"A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents","volume":"106","author":"Winner","year":"2000","journal-title":"Pediatrics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/head.12555","article-title":"Consistency of response to sumatriptan\/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence","volume":"55","author":"Winner","year":"2015","journal-title":"Headache"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1851994\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:11:25Z","timestamp":1784095885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1851994\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":51,"alternative-id":["10.3389\/fphar.2026.1851994"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1851994","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"1851994"}}